학술논문
Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry
Document Type
article
Author
Alessandro Busca; Jon Salmanton-García; Francesco Marchesi; Francesca Farina; Guldane Cengiz Seval; Jaap Van Doesum; Nick De Jonge; Nathan C. Bahr; Johan Maertens; Joseph Meletiadis; Nicola S. Fracchiolla; Barbora Weinbergerová; Luisa Verga; Zdeněk Ráčil; Moraima Jiménez; Andreas Glenthøj; Ola Blennow; Alina Daniela Tanase; Martin Schönlein; Lucia Prezioso; Nina Khanna; Rafael F. Duarte; Pavel Žák; Marcio Nucci; Marina Machado; Austin Kulasekararaj; Ildefonso Espigado; Elizabeth De Kort; José-María Ribera-Santa Susana; Monia Marchetti; Gabriele Magliano; Iker Falces-Romero; Osman Ilhan; Emanuele Ammatuna; Sofia Zompi; Panagiotis Tsirigotis; Anastasia Antoniadou; Giovanni Paolo Maria Zambrotta; Anna Nordlander; Linda Katharina Karlsson; Michaela Hanakova; Giulia Dragonetti; Alba Cabirta; Caroline Berg Venemyr; Stefanie Gräfe; Jens Van Praet; Athanasios Tragiannidis; Verena Petzer; Alberto López-García; Federico Itri; Ana Groh; Eleni Gavriilaki; Michelina Dargenio; Laman Rahimli; Oliver A. Cornely; Livio Pagano; EPICOVIDEHA Consortium; Juergen Prattes; Malgorzata Mikulska; Gustavo-Adolfo Méndez; Tobias Lahmer; Pavel Jindra; Anna Guidetti; Rita Fazzi; Maria Ilaria Del Principe; Cristina De Ramón; Maria Calbacho; Zlate Stojanoski; Andrés Soto; Alexandra Serris; Irati Ormazabal-Vélez; Ali S. Omrani; Milan Navrátil; Sonia Martín-Pérez; Joyce Marques De Almeida; Sylvain Lamure; Martin Kolditz; Ozren Jaksic; Martin Hoenigl; Carolina Garcia-Vidal; Noemí Fernández; Shaimaa El-Ashwah; Natasha Čolović; Martin Čerňan; Caterina Buquicchio; Valentina Bonuomo; Josip Batinić; Murtadha Al-Khabori; Tatjana Adžić-Vukičević; Juan-Alberto Martín-González; Maria Vittoria Sacchi; María-Josefa Jiménez-Lorenzo; Dominik Wolf; Maria Vehreschild; Raul Cordoba; Ramón García-Sanz; Toni Valković; Miloš Mladenović; Nicole García-Poutón; Ziad Emarah; Julio Dávila-Valls
Source
Frontiers in Immunology, Vol 14 (2023)
Subject
Language
English
ISSN
1664-3224
Abstract
BackgroundThe outcome of COVID-19 in allogeneic hematopoietic stem cell transplantation (HSCT) recipients is almost uniformely considered poor. The aim of present study was to retrospectively analyse the outcome and risk factors for mortality in a large series of patients who developed COVID-19 infection after an allogeneic HSCT.MethodsThis multicenter retrospective study promoted by the European Hematology Association – Infections in Hematology Study Working Group, included 326 adult HSCT patients who had COVID-19 between January 2020 and March 2022.ResultsThe median time from HSCT to the diagnosis of COVID-19 was 268 days (IQR 86-713; range 0-185 days). COVID-19 severity was mild in 21% of the patients, severe in 39% and critical in 16% of the patients. In multivariable analysis factors associated with a higher risk of mortality were, age above 50 years, presence of 3 or more comorbidities, active hematologic disease at time of COVID-19 infection, development of COVID-19 within 12 months of HSCT, and severe/critical infections. Overall mortality rate was 21% (n=68): COVID-19 was the main or secondary cause of death in 16% of the patients (n=53).ConclusionsMortality in HSCT recipients who develop COVID-19 is high and largely dependent on age, comorbidities, active hematologic disease, timing from transplant and severity of the infection.